TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,980,337 | -26.9% | 333,371 | +25.6% | 0.00% | -33.3% |
| Q2 2023 | $4,077,496 | -49.9% | 265,462 | -26.7% | 0.00% | -50.0% |
| Q1 2023 | $8,142,976 | +166.7% | 362,071 | +149.3% | 0.01% | +200.0% |
| Q4 2022 | $3,053,724 | -35.2% | 145,208 | -24.1% | 0.00% | -33.3% |
| Q3 2022 | $4,715,000 | +42.1% | 191,384 | +39.8% | 0.00% | +50.0% |
| Q2 2022 | $3,317,000 | +330.8% | 136,894 | +358.7% | 0.00% | – |
| Q1 2022 | $770,000 | -82.8% | 29,845 | -79.3% | 0.00% | -100.0% |
| Q4 2021 | $4,482,000 | -21.6% | 144,384 | -38.8% | 0.00% | -33.3% |
| Q3 2021 | $5,719,000 | +86.2% | 235,827 | +12.0% | 0.00% | +50.0% |
| Q2 2021 | $3,071,000 | -1.6% | 210,519 | +68.5% | 0.00% | 0.0% |
| Q1 2021 | $3,120,000 | +848.3% | 124,941 | +935.1% | 0.00% | – |
| Q4 2020 | $329,000 | – | 12,070 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |